Sexual Health Partnering Terms and Agreements

Published by: Current Partnering

Published: Sep. 1, 2012 - 595 Pages


Table of Contents

Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in sexual health dealmaking
2.1. Introduction
2.2. Sexual health partnering over the years
2.3. Bigpharma sexual health dealmaking activity
2.4. Bigpharma not active in sexual health
2.5. Sexual health partnering by deal type
2.6. Sexual health partnering by industry sector
2.7. Sexual health partnering by stage of development
2.8. Sexual health partnering by technology type
2.9. Sexual health partnering by sexual health indication
2.10. Average deal terms for Sexual health
2.10.1 Sexual health headline values
2.10.2 Hematology upfront payments
2.10.3 Sexual health milestone payments
2.10.4 Sexual health royalty rates
Chapter 3 – Leading sexual health deals
3.1. Introduction
3.2. Top sexual health deals by value
3.3. Top sexual health deals involving bigpharma
Chapter 4 – Bigpharma sexual health deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma sexual health partnering company profiles
Abbott
Bayer
GlaxoSmithKline
Menarini
Merck & Co
Mylan
Pfizer
Roche
Teva
Valeant
Warner Chilcott
Watson
Chapter 5 – Sexual health partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Collaborative R&D
Development
Distribution
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Settlement
Sub-license
Termination
5.3. By stage of development
Formulation
Marketed
Phase II
Phase III
Preclinical
Regulatory
5.4. By technology type
Biological compounds
Devices
Diagnostics
Drug delivery
Small molecules
Chapter 6 – Sexual health dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Sexual Health
Bacterial vaginosis
Candida albicans (Thrush)
Contraception
Erectile dysfunction
Sexual dysfunction
Sexually transmitted disease (STI)
Chlamydia
Genital warts
Gonorrhea
Herpes
Syphilis
Trichomoniasis
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Directory of sexual health deals by company A-Z 2007-2012
Appendix 2 – Directory of sexual health deals by deal type 2007-2012
Appendix 3 – Directory of sexual health deals by stage of development 2007-2012
Appendix 4 – Directory of sexual health deals by technology type 2007-2012
Appendix 5 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
Table of figures
Figure 1: Sexual health partnering since 2007
Figure 2: Bigpharma – top 50 – sexual health deals 2007 to 2012
Figure 3: Bigpharma sexual health deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in sexual health 2007-2012
Figure 5: Sexual health partnering by deal type since 2007
Figure 6: Sexual health partnering by industry sector since 2007
Figure 7: Sexual health partnering by stage of development since 2007
Figure 8: Sexual health partnering by technology type since 2007
Figure 9: Sexual health partnering by sexual health target since 2007
Figure 10: Sexual health deals with a headline value
Figure 11: Sexual health deal headline value distribution, US$million – discovery stage
Figure 12: Sexual health deal headline value distribution, US$million – preclinical stage
Figure 13: Sexual health deal headline value distribution, US$million – phase I stage
Figure 14: Sexual health deal headline value distribution, US$million – phase II stage
Figure 15: Sexual health deal headline value distribution, US$million – phase III stage
Figure 16: Sexual health deal headline value distribution, US$million – regulatory stage
Figure 17: Sexual health deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2012
Figure 19 Sexual Health deals with upfront payment values
Figure 20: Sexual health deal upfront payment distribution, US$million – discovery stage
Figure 21: Sexual health deal upfront payment distribution, US$million – preclinical stage
Figure 22: Sexual health deal upfront payment distribution, US$million – phase I stage
Figure 23: Sexual health deal upfront payment distribution, US$million – phase II stage
Figure 24: Sexual health deal upfront payment distribution, US$million – phase III stage
Figure 25: Sexual health deal upfront payment distribution, US$million – regulatory stage
Figure 26: Sexual health deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2012
Figure 28: Sexual health deals with milestone payments
Figure 29: Sexual health deal milestone distribution, US$million – discovery stage
Figure 30: Sexual health deal milestone distribution, US$million – preclinical stage
Figure 31: Sexual health deal milestone distribution, US$million – phase I stage
Figure 32: Sexual health deal milestone distribution, US$million – phase II stage
Figure 33: Sexual health deal milestone distribution, US$million – phase III stage
Figure 34: Sexual health deal milestone distribution, US$million – regulatory stage
Figure 35: Sexual health deal milestone distribution, US$million – marketed stage
Figure 36: Sexual health deals with royalty rates, %
Figure 37: Sexual health deal royalty rate distribution, US$million – discovery stage
Figure 38: Sexual health deal royalty rate distribution, US$million – preclinical stage
Figure 39: Sexual health deal royalty rate distribution, US$million – phase I stage
Figure 40: Sexual health deal royalty rate distribution, US$million – phase II stage
Figure 41: Sexual health deal royalty rate distribution, US$million – phase III stage
Figure 42: Sexual health deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2012
Figure 45: Top sexual health deals by value since 2007
Figure 46: Top sexual health deals signed by bigpharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in sexual health dealmaking
2.1. Introduction
2.2. Sexual health partnering over the years
2.3. Bigpharma sexual health dealmaking activity
2.4. Bigpharma not active in sexual health
2.5. Sexual health partnering by deal type
2.6. Sexual health partnering by industry sector
2.7. Sexual health partnering by stage of development
2.8. Sexual health partnering by technology type
2.9. Sexual health partnering by sexual health indication
2.10. Average deal terms for Sexual health
2.10.1 Sexual health headline values
2.10.2 Hematology upfront payments
2.10.3 Sexual health milestone payments
2.10.4 Sexual health royalty rates
Chapter 3 – Leading sexual health deals
3.1. Introduction
3.2. Top sexual health deals by value
3.3. Top sexual health deals involving bigpharma
Chapter 4 – Bigpharma sexual health deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma sexual health partnering company profiles
Abbott
Bayer
GlaxoSmithKline
Menarini
Merck & Co
Mylan
Pfizer
Roche
Teva
Valeant
Warner Chilcott
Watson
Chapter 5 – Sexual health partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Collaborative R&D
Development
Distribution
Joint venture
Licensing
Manufacturing
Marketing
Material transfer
Settlement
Sub-license
Termination
5.3. By stage of development
Formulation
Marketed
Phase II
Phase III
Preclinical
Regulatory
5.4. By technology type
Biological compounds
Devices
Diagnostics
Drug delivery
Small molecules
Chapter 6 – Sexual health dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Sexual Health
Bacterial vaginosis
Candida albicans (Thrush)
Contraception
Erectile dysfunction
Sexual dysfunction
Sexually transmitted disease (STI)
Chlamydia
Genital warts
Gonorrhea
Herpes
Syphilis
Trichomoniasis
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
Appendix 1 – Directory of sexual health deals by company A-Z 2007-2012
Appendix 2 – Directory of sexual health deals by deal type 2007-2012
Appendix 3 – Directory of sexual health deals by stage of development 2007-2012
Appendix 4 – Directory of sexual health deals by technology type 2007-2012
Appendix 5 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
Table of figures
Figure 1: Sexual health partnering since 2007
Figure 2: Bigpharma – top 50 – sexual health deals 2007 to 2012
Figure 3: Bigpharma sexual health deal frequency – 2007 to 2012
Figure 4: Inactive bigpharma in sexual health 2007-2012
Figure 5: Sexual health partnering by deal type since 2007
Figure 6: Sexual health partnering by industry sector since 2007
Figure 7: Sexual health partnering by stage of development since 2007
Figure 8: Sexual health partnering by technology type since 2007
Figure 9: Sexual health partnering by sexual health target since 2007
Figure 10: Sexual health deals with a headline value
Figure 11: Sexual health deal headline value distribution, US$million – discovery stage
Figure 12: Sexual health deal headline value distribution, US$million – preclinical stage
Figure 13: Sexual health deal headline value distribution, US$million – phase I stage
Figure 14: Sexual health deal headline value distribution, US$million – phase II stage
Figure 15: Sexual health deal headline value distribution, US$million – phase III stage
Figure 16: Sexual health deal headline value distribution, US$million – regulatory stage
Figure 17: Sexual health deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2007-2012
Figure 19 Sexual Health deals with upfront payment values
Figure 20: Sexual health deal upfront payment distribution, US$million – discovery stage
Figure 21: Sexual health deal upfront payment distribution, US$million – preclinical stage
Figure 22: Sexual health deal upfront payment distribution, US$million – phase I stage
Figure 23: Sexual health deal upfront payment distribution, US$million – phase II stage
Figure 24: Sexual health deal upfront payment distribution, US$million – phase III stage
Figure 25: Sexual health deal upfront payment distribution, US$million – regulatory stage
Figure 26: Sexual health deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2012
Figure 28: Sexual health deals with milestone payments
Figure 29: Sexual health deal milestone distribution, US$million – discovery stage
Figure 30: Sexual health deal milestone distribution, US$million – preclinical stage
Figure 31: Sexual health deal milestone distribution, US$million – phase I stage
Figure 32: Sexual health deal milestone distribution, US$million – phase II stage
Figure 33: Sexual health deal milestone distribution, US$million – phase III stage
Figure 34: Sexual health deal milestone distribution, US$million – regulatory stage
Figure 35: Sexual health deal milestone distribution, US$million – marketed stage
Figure 36: Sexual health deals with royalty rates, %
Figure 37: Sexual health deal royalty rate distribution, US$million – discovery stage
Figure 38: Sexual health deal royalty rate distribution, US$million – preclinical stage
Figure 39: Sexual health deal royalty rate distribution, US$million – phase I stage
Figure 40: Sexual health deal royalty rate distribution, US$million – phase II stage
Figure 41: Sexual health deal royalty rate distribution, US$million – phase III stage
Figure 42: Sexual health deal royalty rate distribution, US$million – regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2012
Figure 45: Top sexual health deals by value since 2007
Figure 46: Top sexual health deals signed by bigpharma value since 2007
Figure 47: Online partnering resources
Figure 48: Forthcoming partnering events

Abstract

The Sexual Health Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the sexual health partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter sexual health partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors sexual health technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual sexual health deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of sexual health dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in sexual health dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading sexual health deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of sexual health deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all sexual health deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all sexual health partnering deals signed and announced since 2007. The chapter is organized by specific sexual health therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all sexual health partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in sexual health partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of sexual health technologies and products.

Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.